The effects of growth factors on Tenon's capsule fibroblasts in serum-free culture.
This study was performed to develop and improve a completely defined in vitro ocular wound-healing model of fibroblast proliferation for glaucoma filtration surgery. This model is essential for the investigation of protein-sensitive drugs and cytokines. Tenon's capsule fibroblasts in their third passage were incubated overnight, washed free of serum, and fed defined media, Aim V or Clonetics FBM serum-free medium containing platelet-derived growth factor, basic fibroblast growth factor, epidermal growth factor, or fibronectin at various dilutions and in combinations at optimum concentrations. Proliferation was measured by 3H-thymidine incorporation at 1, 3, and 7 days. Morphology was compared to controls fed Minimum Essential Medium + 10% serum. Single factors stimulated the greatest amount of thymidine uptake on day 3. Optimum concentrations were epidermal growth factor at 5 ng/ml, basic fibroblast growth factor at 10 ng/ml and platelet-derived growth factor at 20 ng/ml. Identical combinations of factors stimulated nearly twice the thymidine uptake in Clonetics medium as in Aim V. Epidermal growth factor activity was inhibited by either basic fibroblast growth factor or platelet-derived growth factor. Basic fibroblast growth factor and platelet-derived growth factor together produced a less than additive effect. The performance of either serum-free medium may be improved by the addition of basic fibroblast growth factor or platelet-derived growth factor. The optimum serum-free medium (Clonetics FBM) with growth factors was unable to stimulate proliferation as much as Minimum Essential Medium + 10% NBS, but was successful in maintaining viability during the 7 day test period.
Ellis
D G
DG
Jules Stein Eye Institute, Department of Opththalmology, UCLA School of Medicine 90095-7004, USA.
Cheng
Q
Q
Lee
D A
DA
D002455:Cell Division; D002478:Cells, Cultured; D003238:Connective Tissue / Q000187:drug effects* / Q000378:metabolism; D003239:Connective Tissue Cells; D016895:Culture Media, Serum-Free; D004338:Drug Combinations; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005123:Eye / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D005353:Fibronectins / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D009994:Osmolar Concentration; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D013936:Thymidine / Q000378:metabolism
D016895:Culture Media, Serum-Free; D004338:Drug Combinations; D005353:Fibronectins; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D013936:Thymidine